Short- and intermediate-term carcinogenicity testing - A Review. Part 1: The prototypes mouse skin tumour assay and rat liver focus assay

Food and Chemical Toxicology

Volumn 36, Issue 11, 1998, Pages 979-995

  Enzmann, H ^a   Bomhard, E ^a   Iatropoulos, M ^b   Ahr, H J ^a   Schlueter, G ^a   Williams, G M ^b  

^a BAYER AG   (Germany)

^b AMERICAN HEALTH FOUNDATION   (United States)

Author keywords

Carcinogenicity; Chronic rodent bioassay; Enzyme altered foci; Extrapolation; Initiation; Intermediate term; Interspecies correlation; Mouse skin; Neoplasia; Papilloma; Preneoplasia; Promotion; Rat liver; Short term

Indexed keywords

LIVER ENZYME;

ANIMAL MODEL; CARCINOGENICITY; DOSE RESPONSE; DRUG SCREENING; ENZYME ACTIVITY; LIVER FOCAL NODULAR HYPERPLASIA; METHODOLOGY; MOUSE; NONHUMAN; RAT; REVIEW; SKIN TUMOR; STANDARDIZATION;

ANIMALIA; RODENTIA;

EID: 0032211432     PISSN: 02786915     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0278-6915(98)00063-5     Document Type: Review

References (194)

1. Appel K. E., Fürstenberger G., Hapke H. J., Hecker E., Hildebrandt A. G., Koransky W., Marks F., Neumann H. G., Ohnesorge F. K., Schulte-Hermann R. Chemical carcinogenesis, definition of frequently used terms. Cancer Research and Clinical Oncology. 116:1990;232-236.
2. Argyris T. S. Regeneration and the mechanism of epidermal tumor promotion. Critical Reviews in Toxicology. 14:1985;211-258.
3. Baer A. Significance of Leydig-cell neoplasia in rats fed lactitol or lactose. Journal of the American College of Toxicology. 11:1992;189-207.
4. Baetcke K. P., Hard G. C. and Rodgers I. S. (1991) α2μ- globulin, association with chemically induced renal toxicity and neoplasia in the male rat. Risk Assessment Forum. US Environmental Protection Agency 625/3-91/019F Washington DC.
5. Bannasch P. The cytoplasm of hepatocytes during carcinogenesis. Electron and light microscopical investigations of the nitrosomorpholine-intoxicated rat liver. Recent Results in Cancer Research. 19:1968;1-100.
6. Bannasch P. Preneoplastic lesions as end points in carcinogenicity testing. I. Hepatic preneoplasia. Carcinogenesis. 7:1986;689-695.
7. Bannasch P. Preneoplastic lesions as end points in carcinogenicity testing. II. Preneoplasia in various non-hepatic tissues. Carcinogenesis. 7:1986;849-852.
8. Bannasch P., Benner U., Enzmann H., Hacker H. J. Tigroid cell foci and neoplastic nodules in the liver of rats treated with a single dose of aflatoxin B1. Carcinogenesis. 6:1985;1641-1648.
9. Bannasch P., Enzmann H., Hacker H. J., Weber E. and Zerban H. (1989a) Comparative pathobiology of hepatic preneoplasia. In Liver Cell Carcinoma, ed. P. Bannasch, D. Keppler and G. Weber, pp. 55-76. MTP Press, Lancaster.
10. Bannasch P., Enzmann H., Klimek F., Weber E., Zerban H. Significance of sequential cellular changes inside and outside foci of altered hepatocytes during hepatocarcinogenesis. Toxicologic Pathology. 17:1989;617-629.
11. Beasley R. P. Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer. 61:1988;1942-1956.
12. Berenblum I. (1974) Carcinogenesis as a Biological Problem. In Frontiers of Biology, ed. A. Neuberger and E. L. Tatum, pp. 97-112. North Holland Publishing Company, Amsterdam.
13. Berenblum J., Shubik P. A new quantitative approach to the study of the stages of chemical carcinogenesis in the mouse's skin. British Journal of Cancer. 1:1947;389-391.
14. Bickis M., Krewski D. Statistical issues in the analysis of the long term carcinogenicity bioassay in small rodents: an empirical evaluation of statistical decision rules. Fundamental and Applied Toxicology. 12:1989;202-221.
15. Brown K., Balmain A. Transgenic mice and squamous multistage skin carcinogenesis. Cancer and Metastasis Reviews. 14:1995;113-124.
16. Campbell H. A., Pitot H. C., Potter V. R., Laishes B. A. Application of quantitative stereology to the evaluation of enzyme-altered foci in rat liver. Cancer Research. 42:1982;465-472.
17. Campbell T. C., Chen J. S., Liu C. B., Li J. Y., Parpia B. Nonassociation of aflatoxin with primary liver cancer in a cross-sectional ecological survey in the People's Republic of China. Cancer Research. 50:1990;6882-6893.
18. Carmichael N. G., Enzmann H., Pate I., Waechter F. The significance of mouse liver tumor formation for carcinogenic risk assessment: results and conclusions from a survey of ten years of testing by the agrochemical industry. Environmental Health Perspectives. 105:1997;1196-1203.
19. Cayama E., Tsuda H., Sarma D. S. R., Farber E. Initiation of chemical carcinogenesis requires cell proliferation. Nature. 275:1978;60-62.
20. Chu K. C., Brown C. C., Tarone R. E., Tan W. Y. Differentiating among proposed mechanisms for tumor promotion in mouse skin with the use of the multievent model for cancer. Journal of the National Cancer Institute. 79:1987;789-796.
21. Coffey R. J. Jr, Meise K. S., Matsui Y., Hogan B. L., Dempsey P. J., Halter S. A. Acceleration of mammary neoplasia in transforming growth factor alpha transgenic mice by 7,12-dimethylbenzanthracene. Cancer Research. 54:1994;1678-1683.
22. Cohen S. M., Ellwein L. B. Use of cell proliferation data in modeling urinary bladder carcinogenesis. Environmental Health Perspectives. 101:1993;111-113.
23. Contrera J., Jacobs A. C., DeGeorge J. J. Carcinogenicity testing and the evaluation of regulatory requirements for pharmaceuticals. Regulatory Toxicology and Pharmacology. 25:1997;130-145.
24. Counts J. L., Goodman J. I. Principles underlying dose selection for, and extrapolation from, the carcinogen bioassay - dose influences mechanism. Regulatory Toxicology and Pharmacology. 21:1995;418-421.
25. Craddock V. M. Liver carcinomas induced in rats by single administration of dimethylnitrosamine after partial hepatectomy. Journal of the National Cancer Institute. 47:1971;899-907.
26. Cunningham M. L., Elwell M. R., Matthews H. B. Site-specific cell proliferation in renal tubular cells by the renal tubular carcinogen tris(2,3-dibromopropyl)phosphate. Environmental Health Perspectives. 101:1993;253-257.
27. De Gerlache J., Lans M., Taper H., Préat V. and Roberfroid M. (1982) Promotion of the chemically initiated hepatocarcinogenesis. In Mutagens in our Environment, ed. M. Sorsa and H. Vaina, pp. 35-46. Liss, New York.
28. De Koster E., Buset M., Fernandes E., Deltenre M. Helicobacter pylori, the link with gastric cancer. European Journal of Cancer Prevention. 3:1994;247-257.
29. Deml E., Oesterle D., Wolff T., Greim H. Age-, sex-, and strain-dependent differences in the induction of enzyme-altered islands in rat liver by diethylnitrosamine. Journal of Cancer Research and Clinical Oncology. 100:1981;125-134.
30. DiGiovanni J. Multistage carcinogenesis in mouse skin. Pharmacology and Therapeutics. 54:1992;63-128.
31. DiGiovanni J., Rho O., Xian W., Beltran L. Role of the epidermal growth factor receptor and transforming growth factor alpha in mouse skin carcinogenesis. Progress in Clinical and Biological Research. 387:1994;113-138.
32. Dragan Y. P., Hully J., Crow R., Mass M., Pitot H. C. Incorporation of bromodeoxyuridine in glutathione S-transferase-positive hepatocytes during rat multistage hepatocarcinogenesis. Carcinogenesis. 15:1994;1939-1947.
33. Dragan Y. P., Rizvi T., Xu Y. H., Hully J. R., Bawa N., Campbell H. A., Maronpot R. R., Pitot H. C. An initiation-promotion assay in rat liver as a potential complement to the 2-year carcinogenesis bioassay. Fundamental and Applied Toxicology. 16:1991;525-542.
34. Dragan Y. P., Xu X. H., Goldsworthy T. L., Campbell H. A., Maronpot R. R., Pitot H. C. Characterization of the promotion of altered hepatic foci by 2,3,7,8-tetrachlorodibenzo-p-dioxin in the female rat. Carcinogenesis. 13:1992;1389-1395.
35. Edler L., Schmidt R., Weber E., Rippmann F., Hecker E. Biological assays for irritant tumor-initiating and -promoting activities. III. Computer-assisted management and validation of biodata generated by standardized initiation/promotion protocols in skin of mice. Journal of Cancer Research and Clinical Oncology. 117:1991;205-216.
36. Emmelot P., Scherer E. The first relevant stage in rat liver carcinogenesis: a quantitative approach. Biochimica et Biophysica Acta. 605:1980;247-304.
37. Enzmann H., Bannasch P. Potential significance of phenotypic heterogeneity of focal lesions at different stages in hepatocarcinogenesis. Carcinogenesis. 8:1987;1607-1612.
38. Enzmann H., Bannasch P. Non-persisting early foci of altered hepatocytes induced in rats by N-nitrosomorpholine. Journal of Cancer Research and Clinical Oncology. 114:1988;30-34.
39. Enzmann H., Edler L., Bannasch P. Simple elementary method for the quantification of focal liver lesions induced by carcinogens. Carcinogenesis. 8:1987;231-235.
40. Enzmann H., Ohlhauser D., Dettler T., Bannasch P. Enhancement of hepatocarcinogenesis in rats by dietary fructose. Carcinogenesis. 10:1989;1247-1252.
41. Enzmann H., Ohlhauser D., Dettler T., Benner U., Hacker H. J., Bannasch P. Unusual histochemical pattern in preneoplastic hepatic foci characterized by hyperactivity of several enzymes. Virchows Archiv B. 57:1989;99-108.
42. Enzmann H., Zerban H., Kopp-Schneider A., Löser E., Bannasch P. Effects of low doses of N-nitrosomorpholine on the development of early stages of hepatocarcinogesis. Carcinogenesis. 16:1995;1513-1518.
43. Enzmann H., Zerban H., Löser E., Bannasch P. Glycogen phosphorylase hyperactive foci of altered hepatocytes in aged rats. Virchows Archiv B. 62:1992;3-8.
44. Farber E. Chemical carcinogenesis, a current biological perspective. Carcinogenesis. 5:1984;1-5.
45. Fischer G., Hartmann H., Droese M., Schauer A., Bock K. W. Histochemical and immunohistochemical detection of putative preneoplastic liver foci in women after long-term use of oral contraceptives. Virchows Archiv B. 50:1986;321-337.
46. Friedwald W. F., Rous P. Initiating and promoting elements in tumor production; analysis of effects of tar, benzpyrene and methylcholanthrene on rabbit skin. Journal of Experimental Medicine. 80:1944;101-126.
47. Fuerstenberger G., Kopp-Schneider A. Malignant progression of papillomas induced by the initiation promotion protocol in NMRI mouse skin. Carcinogenesis. 16:1995;61-69.
48. Fuerstenberger G., Marks F. and Fusenig N. E. (1985) Prostaglandins, epidermal hyperplasia and skin tumor promotion. In Arachidonic Acid Metabolism and Tumor Promotion, ed. S. M. Fischer and T. J. Slaga, pp. 49-72. Nijoff Publishers, Boston.
49. Fuerstenberger G., Schurich B., Kaina B., Petrusevska R. T., Fusenig N. E., Marks F. Tumor induction in initiated mouse skin by phorbol esters and methyl methanesulfonate, correlation between chromosomal damage and conversion in vivo. Carcinogenesis. 10:1989;719-723.
50. Fullman R. L. Measurement of particle sizes in opaque bodies. Trans. AIME. 197:1953;447-452.
51. Glauert H. P., Beaty M. M., Clark T. D., Greenwell W. S., Tatum V., Chen L. C., Borges T., Clark T. L., Srinivasan S. R., Chow C. K. Effect of dietary vitamin E on the development of altered hepatic foci and hepatic tumors induced by the peroxisome proliferator ciprofibrate. Journal of Cancer Research and Clinical Oncology. 116:1990;351-356.
52. Glauert H. P., Beer D., Rao M. S., Schwarz M., Xu Y. D., Goldsworthy T. L., Coloma J., Pitot H. C. Induction of altered hepatic foci in rats by the administration of hypolipidemic peroxisome proliferators alone or following a single dose of diethylnitrosamine. Cancer Research. 46:1986;4601-4606.
53. Gold L. S., Manley N. B., Ames B. N. Extrapolation of carcinogenicity between species, qualitative and quantitative factors. Risk Analysis. 12:1992;579-588.
54. Gold L. S., Slone T. H., Stern B. R., Bernstein L. Comparison of target organs of carcinogenicity for mutagenic and non-mutagenic chemicals. Mutation Research. 286:1993;75-100.
55. Goldsworthy T. L., Campbell H. A., Pitot C. The natural history and dose-response characteristics of enzyme-altered foci in rat liver following phenobarbital and diethylnitrosamine administration. Carcinogenesis. 5:1984;67-71.
56. össner and Friedrich-Freksa, 1964.
57. Gössner W., Friedrich-Freksa H. Histochemische Untersuchungen über die Glucose- Phosphatase in der Rattenleber während der Kanzerisierung durch Nitrosamine. Zeitschrift für Naturforschung. 19b:1964;862-863.
58. Greenhalgh D. A., Wang X. J., Roop D. R. Multistage skin carcinogenesis in transgenic mice. Proceedings of the Association of American Physicians. 107:1995;258-275.
59. Hacker H. J., Moore M. A., Mayer D., Bannasch P. Correlative histochemistry of some enzymes of carbohydrate metabolism in preneoplastic and neoplastic lesions in the rat liver. Carcinogenesis. 3:1982;1265-1272.
60. Hanigan M. H., Winkler M. L., Drinkwater N. R. Partial hepatectomy is a promoter of hepatocarcinogenesis in C57BL/6J male mice but not in C3H/HeJ male mice. Carcinogenesis. 11:1990;589-594.
61. Harris L., Morris L. E., Farber E. Protective value of a liver initiation-promotion regimen against the lethal effect of carbon tetrachloride in rats. Laboratory Investigations. 61:1989;467-470.
62. Hartman P. E., Hartman Z. Direct interception of mutagens and carcinogens by biomolecules. Basic Life Sciences. 61:1993;351-366.
63. Haseman J. K. A reexamination of false-positive rates for carcinogenesis studies. Fundamental and Applied Toxicology. 3:1983;334-339.
64. Haseman J. K. Use of statistical decision rules for evaluating laboratory animal carcinogenicity studies. Fundamental and Applied Toxicology. 14:1990;637-648.
65. Haseman J. K., Lockhart A. M. Correlations between chemically related site-specific carcinogenic effects in long-term studies in rats and mice. Environmental Health Perspectives. 101:1993;50-54.
66. Haseman J. K., Lockhart A. M. The relationship between use of the maximum tolerated dose and study sensitivity for detecting rodent carcinogenicity. Fundamental and Applied Toxicology. 22:1994;382-391.
67. Hatch M. C., Chen C. J., Levin B., Ji B. T., Yang G. Y., Hsu S. W., Wang L. W., Hsieh L. L., Santella R. M. Urinary aflatoxin levels, hepatitis-B virus infection and hepatocellular carcinoma in Taiwan. International Journal of Cancer. 54:1993;931-934.
68. Hei T. K., Sudilovsky O. Effects of a high sucrose diet on the development of enzyme-altered foci in chemical hepatocarcinogenesis in rats. Cancer Research. 45:1985;2700-2705.
69. Hennings H., Glick A. B., Greenhalgh D. A., Morgan D. L., Strickland J. E., Tennenbaum T., Yuspa S. H. Critical aspects of initiation promotion and progression in multistage epidermal carcinogenesis. Proceedings of the Society for Experimental Biology and Medicine. 202:1993;1-8.
70. Hickey R. J., Clelland R. C., Bowers E. J. Essential hormones as carcinogenic hazards. Journal of Occupational Medicine. 21:1979;265-268.
71. Hirota N., Hamazaki M., Williams G. M. Resistance to iron accumulation and presence of hepatitis B surface antigen in preneoplastic and neoplastic lesions in human hemochromatotic livers. Hepatogastroenterology. 29:1982;49-51.
72. Hsing A. W., Guo W., Chen J., Li J. Y., Sone B. J., Blot W. J., Fraumeni J. F. Jr. Correlates of liver cancer mortality in China. International Journal of Epidemiology. 20:1991;54-59.
73. Huang S. N., Chisari F. V. Strong sustained hepatocellular proliferation precedes hepatocarcinogenesis in hepatitis B surface antigen transgenic mice. Hepatology. 21:1995;620-626.
74. Huff J. E. (1992) Chemical toxicity and chemical carcinogenesis. Is there a causal connection? A comparative morphological evaluation of 1500 experiments. IARC Scientific Publications no. 116, pp. 437-475. International Agency for Research on Cancer, Lyon.
75. Hulka B. S., Liu E. T., Lininger R. A. Steroid hormones and risk of breast cancer. Cancer. 74:1994;1111-1124.
76. IARC (1998) Chemical-induced rodent preneoplastic lesions as indicators of carcinogenic activity. IARC Scientific Publications. In press. International Agency for Research on Cancer, Lyon.
77. Iatropoulos M. J. Accelerated rodent bioassay predictive of chemical carcinogenesis. Experimental and Toxicologic Pathology. 44:1992;481-487.
78. Iatropoulos M. J. Endocrine considerations in toxicologic pathology. Experimental and Toxicologic Pathology. 45:1993/94;391-410.
79. Iball J. The relative potencies of carcinogenic compounds. American Journal of Cancer. 35:1939;188-190.
80. International Conference on Harmonisation; Draft Guideline on dose selection for carcinogenicity studies of pharmaceuticals; addendum on the limit dose. Federal Register. 62:1997;15715-15716.
81. ICH4 (1997) Fourth International Conference on Harmonisation: Carcinogenicity: testing for carcinogenicity of pharmaceuticals. Brussels, 16-18 July.
82. Imaida K., Tatematsu M., Kato T., Tsuda H., Ito N. Advantages and limitations of the stereological estimation of placental glutathione S-transferase positive rat liver cell foci by computerized three-dimensional reconstruction. Japanese Journal of Cancer Research. 80:1989;326-330.
83. Infante P. F. Use of rodent carcinogenicity assay results for determining potential cancer risk to humans. Environmental Health Perspectives. 101:1993;143-148.
84. Ishikawa T., Takayama S., Kitagawa T. Correlation between time of partial hepatectomy after a single treatment with diethylnitrosamine and induction of adenosinetriphosphatase-deficient islands in rat liver. Cancer Research. 40:1980;4261-4264.
85. Ito N., Hasegawa R., Imaida K., Masui T., Takahashi S., Shirai T. Pathological markers for non-genotoxic agent-associated carcinogenesis. Toxicology Letters. 64-65:1992;613-620.
86. Ito N., Hasegawa R., Imaida K., Takahashi S., Shirai T. Medium-term rat liver bioassay for rapid detection of carcinogens and modifiers of hepatocarcinogenesis. Drug Metabolism Review. 26:1994;431-442.
87. Ito N., Hirose M., Imaida K. Antioxidants: Carcinogenic and chemopreventive properties. Encyclopedia of Cancer. 1:1997;51-63.
88. Ito N., Imaida K., Hasegawa R., Tsuda H. Rapid bioassay methods for carcinogens and modifiers of hepatocarcinogenesis. Critical Reviews in Toxicology. 19:1989;386-415.
89. Ito N., Tsuda H., Tatematsu M., Inoue T., Tagawa Y., Aoki T., Satoshi U., Kagawa M., Ogiso T., Masui T., Imaida M., Fukushima S., Asamoto M. Enhancing effect of various hepatocarcinogens on induction of preneoplastic glutathione S-transferase placental form positive foci in rats - an approach for a new medium-term bioassay system. Carcinogenesis. 9:1988;387-394.
90. Kaina B. Chromosomal aberrations as a contributing factor for tumor promotion in the mouse skin. Teratogenesis, Carcinogenesis and Mutagenesis. 9:1989;331-348.
91. Kalengayi M. M. R., Desmet V. J. Sequential histological and histochemical study of the rat liver during aflatoxin B1-induced carcinogenesis. Cancer Research. 35:1975;2845-2852.
92. Kew M. C. (1989) Role of cirrhosis in hepatocarcinogenesis. In Liver Cell Carcinoma, ed. P. Bannasch, D. Keppler and G. Weber, pp. 37-46. Kluwer Academic Publishers, Lancaster, UK.
93. Kinzel V., Fürstenberger G., Loehrke H., Marks F. Three-stage tumorigenesis in mouse skin, DNA synthesis as a prerequisite for the conversion stage induced by TPA prior to initiation. Carcinogenesis. 7:1986;779-782.
94. Kinzel V., Loehrke H., Goerttler K., Fürstenberger G., Marks F. Suppression of the first stage of phorbol 12-tetradecanoate 13-acetate-effected tumor promotion in mouse skin by nontoxic inhibition of DNA synthesis. Proceedings of the National Academy of Sciences of the U.S.A. 81:1984;5858-5862.
95. Kitagawa T., Sugano H. Enhancing effect of phenobarbital on the development of enzyme-altered islands and hepatocellular carcinomas initiated by 3′-methyl-4-(dimethylamino)azobenzene or diethylnitrosamine. Japanese Journal of Cancer Research. 69:1978;679-687.
96. Kitchin K. T., Brown J. L., Setzer R. W. Dose-response relationship in multistage carcinogenesis: promoters. Environmental Health Perspectives. 102:1994;255-264.
97. Kraus A. L., Munro I. C., Orr J. C., Binder R. L., LeBoeuf R. A., Williams G. M. Benzoyl peroxide, an integrated human safety assessment for carcinogenicity. Regulatory Toxicology and Pharmacology. 21:1995;87-107.
98. Larson J. L., Wolf D. C., Butterworth B. E. Induced cytotoxicity and cell proliferation in the hepatocarcinogenicity of chloroform in female B6C3F1 mice: Comparison of administration by gavage in corn oil vs ad libitum in drinking water. Fundamental and Applied Toxicology. 22:1994;90-102.
99. Ledda-Columbano G. M., Coni P., Columbano A. Cell proliferation and cell death in rat liver carcinogenesis by chemicals. Archives of Toxicology. 16:1994;271-280.
100. Ledda-Columbano G. M., Coni P., Simbula G., Zedda I., Columbano A. Compensatory regeneration mitogen-induced liver growth and multistage chemical carcinogenesis. Environmental Health Perspectives. 101:1993;163-168.
101. Lin E. L. C., Klaunig J. E., Mattox J. K., Weghorst C. M., McFarland B. H., Pereira M. A. Comparison of the effects of acute and subacute treatment with phenobarbital in different strains of mice. Cancer Letters. 48:1989;43-51.
102. Lisker-Melman M., Martin P., Hoofnagle J. H. Conditions associated with hepatocellular carcinoma. Medical Clinics of North America. 73:1989;999-1009.
103. Loehrke H., Schweizer J., Dederer E., Hesse B., Rosenkranz G., Goerttler H. On the persistence of tumor initiation in the two stage carcinogenesis on mouse skin. Carcinogenesis. 4:1983;771-775.
104. ürstenberger, 1988.
105. Marks F. and Fuerstenberger G. (1988) Multistage carcinogenesis in animal skin. The reductionist's approach in cancer research. In Theories of Carcinogenesis, ed. H. Iversen, pp. 1179-1891. Hemisphere, London.
106. ürstenberger, 1993.
107. Marks F., Fuerstenberger G. Proliferative responses of the skin to external stimuli. [Review]. Environmental Health Perspectives. 101:1993;95-101.
108. Maronpot R. R., Pitot H. C., Peraino C. Use of rat liver altered focus models for testing chemicals that have completed two-year carcinogenicity studies. Toxicologic Pathology. 17:1989;651-662.
109. Maruyama H., Tanaka T., Williams G. M. Effects of the peroxisome proliferator di(2-ethylhexyl)phthalate on enzymes in rat liver and on carcinogen-induced liver altered foci in comparison to the promoter phenobarbital. Toxicologic Pathology. 18:1990;257-267.
110. Melnick R. L., Huff J. Liver carcinogenesis is not a predicted outcome of chemically induced hepatocyte proliferation. Toxicology and Industrial Health. 9:1993;415-438.
111. Melnick R. L., Huff J., Barrett J. C., Maronpot R. R., Lucier G., Portier C. J. Cell proliferation and chemical carcinogenesis, symposium overview. Environmental Health Perspectives. 101:1993;3-7.
112. Moore M. A., Kitagawa T. Hepatocarcinogenesis in the rat: the effect of promoters and carcinogens in vivo and in vitro. International Review of Cytology. 101:1986;125-173.
113. Naito M., DiGiovanni J. Genetic background and development of skin tumors. Carcinogenesis. 11:1989;187-212.
114. 1 mice, swiss (CD-1) mice and SENCAR mice. Technical Report Series 441. National Toxicology Program. US Department of Health and Human Services, Public Health Service, National Institutes of Health.
115. Carcinogenicity Testing. OECD Guideline for Testing of Chemicals. 451:1981;11-12.
116. Oesterle D., Deml E. Lack of initiating and promoting activity of thiourea in rat liver foci bioassay. Cancer Letters. 41:1988;245-249.
117. Oesterle D., Gerbracht U., Deml E., Schlatterer B., Eigenbrodt E. Comparison of three rat liver foci bioassays-incidence of preneoplastic foci initiated by diethylnitrosamine. Carcinogenesis. 10:1989;1891-1895.
118. Owens D. M., Spalding J. W., Tennant R. W., Smart R. C. Genetic alterations cooperate with v-Ha-ras to accelerate multistage carcinogenesis in TG. AC transgenic mouse skin. Cancer Research. 55:1995;3171-3178.
119. Parkin D. M., Ohshima H., Srivatanakul P., Vatanasapt V. Cholangiocarcinoma, epidemiology mechanisms of carcinogenesis and prevention. Cancer Epidemiology Biomarkers Prevention. 2:1993;537-544.
120. Parnell M. J., Exon J. H., Koller L. D. Assessment of hepatic initiation-promotion properties of trichloroacetic acid. Archives of Environmental Contamination and Toxicology. 17:1988;429-436.
121. Peraino C., Fry R. J. M., Staffeldt E. Reduction and enhancement by phenobarbital of hepatocarcinogenesis induced in the rat by 2-acetylaminofluorene. Cancer Research. 31:1971;1506-1512.
122. Peraino C., Fry R. J. M., Staffeldt E. Effects of varying the onset and duration of exposure to phenobarbital on its enhancement of 2-acetylaminofluorene-induced hepatic tumorigenesis. Cancer Research. 37:1977;3623-3628.
123. Pereira M. A. and Herren-Freund S. L. (1988) Liver Initiation Assay, the Rat Liver Foci Bioassay of Carcinogens and Noncarcinogens. Evaluation of Short-term Assays for Carcinogens, ed. J. Ashby, F. J. de Serres, M. D. Shelby, B. H. Margolin, M. Ishidate and G. C. Becking, pp. 1.325-1.328. Cambridge University Press.
124. Pereira M. A., Herren-Freund S. L., Long R. E. Dose-response relationship of phenobarbital promotion of diethylnitrosamine initiated tumors in rat liver. Cancer Letters. 32:1986;305-311.
125. Pitot H. C., Sirica A. E. The stages of initiation and promotion in hepatocarcinogenesis. Biochimica et Biophysica Acta. 605:1980;191-215.
126. Pitot H. C., Barsness L., Goldsworthy T., Kitagawa T. Biochemical characterization of stages of hepatocarcinogenesis after a single dose of diethylnitrosamine. Nature. 217:1978;456-458.
127. Pitot H. C., Goldsworthy T. L., Moran S., Kennan W., Glauert H. P., Maronpot R. R., Campbell H. A. A method to quantitate the relative initiating and promoting potencies of hepatocarcinogenic agents in their dose-response relationship to altered hepatic foci. Carcinogenesis. 8:1987;1491-1499.
128. Pitot H. C., Gross L. E., Goldsworthy T. Genetics and epigenetics of neoplasia, facts and theories. Carcinogenesis. 10:1985;65-79.
129. Pott P. (1775) Cirurgical Observations Relative to the Cataract, the Polypus of the Nose, the Cancer of the Scrotum, the Different Kinds of Ruptures and the Mortification of the Toes and Feet, ed. Hawes, Clarke and Collins, pp. 63-68. London.
130. Qian G. S., Ross R. K., Yu M. C., Yuan J. M., Gao Y. T., Henderson B. E., Wogan G. N., Groopman J. D. A follow-up study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, People's Republic of China. Cancer Epidemiology, Biomarkers and Prevention. 3:1994;3-10.
131. Reddy A. L., Fialkow P. J. Influence of dose of initiator on two-stage skin carcinogenesis in BALB/c mice with cellular mosaicism. Carcinogenesis. 9:1988;751-754.
132. Rizvi T. A., Kennan W., Xu Y. H., Pitot H. C. The effects of dose and duration of administration on the promotion index of phenobarbital in multistage hepatocarcinogenesis in the rat. Acta Pharmacologica et Microbiologica Scandinavia. 2:1988;262-274.
133. Robinson B. G. Molecular genetics of thyroid and parathyroid neoplasia. Australian & New Zealand Journal of Surgery. 65:1995;77-79.
134. Roe F. J. Perspectives in carbohydrate toxicology with special reference to carcinogenicity. Swedish Dental Journal. 8:1984;99-111.
135. Rosin M. P., Saad el Din Zaki S., Ward A. J., Anwar W. A. Involvement of inflammatory reactions and elevated cell proliferation in the development of bladder cancer in schistosomiasis patients. Mutation Research. 305:1994;283-292.
136. Ruebner B. H., Michas C., Kanayama R., Bannasch P. Sequential hepatic histologic and histochemical changes produced by diethylnitrosamine in the rhesus monkey. Journal of the National Cancer Institute. 57:1976;1262-1267.
137. Sasaki T., Yoshida T. Experimentelle Erzeugung des Lebercarcinoms durch Fütterung mit o-Amidoazotoluol. Virchows Archiv, Pathologische Anatomie. 295:1935;175-200.
138. Sato K., Kitahara A., Satoh K., Ichikawa T., Tatematsu M., Ito N. The placental form of glutathione S-transferase as a new marker protein for preneoplasia in rat chemical carcinogenesis. Japanese Journal of Cancer Research. 75:1984;199-202.
139. Schauer A., Kunze E. Enzymhistochemische und autoradiographische Untersuchungen während der Cancerisierung der Rattenleber mit Diäthylnitrosamin. Zeitschrift für Krebsforschung. 70:1968;252-266.
140. Schmidt R., Hecker E. Biological assays for irritant, tumor-initiating and tumor-promoting activities. II Standardized initiation/promotion protocol and semiquantitative estimation of promoting (or initiating) potencies in skin of NMRI mice. Journal of Cancer Research and Clinical Oncology. 115:1989;516-524.
141. Schulte-Hermann R., Bursch W., Kraupp-Grasl B., Oberhammer F., Wagner A., Jirtle R. Cell-proliferation and apoptosis in normal liver and preneoplastic foci. Environmental Health Perspectives. 101:1993;87-90.
142. Schulte-Hermann R., Timmermann-Trosiener I., Schuppler J. Promotion of spontaneous preneoplastic cells in rat liver as a possible explanation of tumor production by nonmutagenic compounds. Cancer Research. 43:1983;839-844.
143. Short B. G. Cell proliferation and renal carcinogenesis. Environmental Health Perspectives. 101:1993;115-120.
144. Simonetti R. G., Cammà C., Fiorello F., Politi F., D'Amico G., Pagliaro L. Hepatocellular Carcinoma, A worldwide problem and the major risk factors. Digestive Diseases and Sciences. 36:1991;962-972.
145. Slaga T. J. Multistage skin carcinogenesis, a useful model for the study of the chemoprevention of cancer. Acta Pharmacologica et Toxicologica. 55:1984;107-124.
146. Slaga T. J. SENCAR mouse skin tumorigenesis model versus other strains and stocks of mice. Environmental Health Perspectives. 68:1986;27-32.
147. Solt D., Farber E. New principle for the analysis of chemical carcinogenesis. Nature. 263:1976;701-703.
148. Solt D. B., Medline A., Farber E. Rapid emergence of carcinogen-induced hyperplastic lesions in a new model for the sequential analysis of liver carcinogenesis. American Journal of Pathology. 88:1977;595-618.
149. äck et al., 1994.
150. Stenbäck F., Gebhardt R., Sirma H., Garbay J. M., Williams G. M. Sequential functional and morphological alterations during hepatocarcinogenesis induced in rats by feeding of a low dose of 2-acetylaminofluorene. Toxicologic Pathology. 22:1994;620-632.
151. Stone R. A molecular approach to cancer risk. Science. 268:1995;356-357.
152. Sundberg J. P., Sundberg B. A., Beamer W. G. Comparison of chemical carcinogen skin tumor induction efficacy in inbred, mutant, and hybrid strains of mice: morphologic variations of induced tumors and absence of a papilloma virus. Molecular Carcinogenesis. 20:1997;19-32.
153. Swenberg J. J. Alpha(2μ)-globulin nephropathy - Review of the cellular and molecular mechanisms involved and their implications for human risk assessment. Environmental Health Perspectives. 101:1993;39-44.
154. Tanaka T., Mori H., Williams G. M. Enhancement of dimethylnitrosamine-initiated hepatocarcinogenesis in hamsters by subsequent administration of carbon tetrachloride but not phenobarbital or p,p'-dichlorodiphenyltrichloroethane. Carcinogenesis. 8:1987;1171-1178.
155. Thorgeirsson U. P., Dalgard D. W., Reeves J., Adamson R. H. Tumor incidence in a chemical carcinogenesis study of nonhuman-primates. Regulatory Toxicology and Pharmacology. 19:1994;130-151.
156. Tokumo K., Iatropoulos M. J., Williams G. M. Butylated hydroxytoluene lacks the activity of phenobarbital in enhancing diethylnitrosamine-induced mouse liver carcinogenesis. Cancer Letters. 59:1991;193-199.
157. Tsuda H., Masui T., Ikawa E., Imaida K., Ito N. Compared promoting potential of d-galactosamine, carbon tetrachloride and partial hepatectomy in rapid induction of preneoplastic liver lesions in the rat. Cancer Letters. 37:1987;163-171.
158. Tsukada H., Sawada N., Mitaka T., Gotoh M. Effects of liver-tumor promoters on phalloidin sensitivity of rat hepatocytes. Carcinogenesis. 7:1986;335-337.
159. Umemura T., Tokumo K., Sirma H., Gebhardt R., Poirier M. C., Williams G. M. Dose response effects of 2-acetylaminofluorene on DNA damage, cytotoxicity, cell proliferation and neoplastic conversion in rat liver. Cancer Letters. 73:1993;1-10.
160. Umemura T., Tokumo K., Williams G. M. Cell proliferation induced in the kidneys and livers of rats and mice by short term exposure to the carcinogen p-dichlorobenzene. Archives of Toxicology. 66:1992;503-507.
161. Vassar R., Hutton M. E., Fuchs E. Transgenic overexpression of transforming growth factor alpha bypasses the need for c-Ha-ras mutations in mouse skin tumorigenesis. Molecular and Cellular Biology. 12:1992;4643-4653.
162. Vesselinovitch S. D., Hacker H. J., Bannasch P. Histochemical characterization of focal hepatic lesions induced by single diethylnitrosamine treatment in infant mice. Cancer Research. 45:1985;2774-2780.
163. Ward J. M., Uno H., Kurata Y., Weghorst C. M., Jang J. J. Cell proliferation is not associated with carcinogenesis in rodents and humans. Environmental Health Perspectives. 101:1993;125-135.
164. Warwick G. P. Effect of cell cycle on carcinogenesis. Federation Proceedings. 30:1971;1760-1765.
165. Watanabe K., Williams G. M. Enhancement of rat hepatocellular-altered foci by the liver tumor promoter phenobarbital, evidence that foci are precursors of neoplasms and that the promoter acts on carcinogen-induced lesions. Journal of the National Cancer Institute. 61:1978;1311-1314.
166. Weber E., Moore M. A., Bannasch P. Enzyme histochemical and morphological phenotype of amphophilic foci and amphophilic/tigroid cell adenomas in rat liver after combined treatment with dehydroepiandosteron and N-nitrosomorpholine. Carcinogenesis. 9:1988;1049-1054.
167. Weibel E. R. (1979) Stereological Methods. Vol. 1, Practical methods for biological morphometry. Academic Press, London.
168. Weisburger J.H. and Williams G. M. (1982) Classification of carcinogens as genotoxic and epigenetic as basis for improved toxicologic bioassay methods. In Environmental Mutagens and Carcinogens, ed. T. Sugimura, S. Kondo and T. Takebe, pp. 283-294. University of Tokyo Press, Tokyo/Alan R. Liss, Inc, New York.
169. Weisburger J. H. and Williams G. M. (1984) Bioassay of carcinogens: in vitro and in vivo tests. In ACS Monograph 182, Chemical Carcinogens, Vol. 2, ed. C. E. Searle, 2nd Ed. pp. 1323-1373. American Chemical Society, Washington, DC.
170. Whysner J., Ross P. M., Williams G. M. Phenobarbital mechanistic data and risk assessment: enzyme induction, enhanced cell proliferation and tumor promotion. Pharmacology and Therapeutics. 71:1996;153-192.
171. Whysner J., Verna L., English J. C., Williams G. M. Analysis of studies related to tumorigenicity induced by hydroquinone. Regulatory Toxicology and Pharmacology. 21:1995;158-176.
172. Whysner J., Williams G. M. International cancer risk assessment, the impact of biologic mechanisms. Regulatory Toxicology and Pharmacology. 15:1992;41-50.
173. Whysner J., Williams G. M. D-limonene mechanistic data and risk assessment: absolute species-specific cytotoxicity, enhanced cell proliferation and tumor promotion. Pharmacology and Therapeutics. 71:1996;127-136.
174. Williams G. M. The pathogenesis of rat liver cancer caused by chemical carcinogens. Biochimica et Biophysica Acta. 605:1980;167-189.
175. Williams G. M. Phenotypic properties of preneoplastic rat liver lesions and applications to detection of carcinogens and tumor promoters. Toxicologic Pathology. 10:1982;3-10.
176. Williams G. M. The significance of chemically-induced hepatocellular altered foci in rat liver and application to carcinogen detection. Toxicologic Pathology. 17:1989;663-672.
177. Williams G. M. DNA reactive and epigenetic carcinogens. Experimental and Toxicologic Pathology. 44:1992;457-463.
178. Williams G. M. Chemicals with carcinogenic activity in the rodent liver; mechanistic evaluation of human risk. Cancer Letters. 117:1997;175-188.
179. Williams G. M., Baker III G. T. The potential relationships between aging and cancer. Experimental Gerontology. 27:1992;469-476.
180. Williams G. M., Gebhardt R., Sirma H., Stenback F. Non-linearity of neoplastic conversion induced in rat liver by low exposures to diethylnitrosamine. Carcinogenesis. 14:1993;2149-2156.
181. Williams G. M., Iatropoulos M. J., Weisburger J. H. Chemical carcinogen mechanisms of action implications for testing methodology. Experimental and Toxicologic Pathology. 48:1996;101-111.
182. Williams G. M., Klaiber M., Parker S. E., Farber E. Nature of early appearing, carcinogen-induced liver lesions resistant to iron accumulation. Journal of the National Cancer Institute. 57:1976;157-165.
183. Williams G. M. and Weisburger J. H. (1991) Chemical carcinogenesis. In Casarett and Doull's Toxicology. The Basic Science of Poisons, ed. M. O. Amdur, J. Doull and C. D. Klaassen, 4th Ed. pp. 127-200. Pergamon, New York.
184. Williams G. M., Whysner J. Epigenetic carcinogenesis, Evaluation and risk assessment. Experimental and Toxicologic Pathology. 48:1996;189-195.
185. Yamagiwa K., Ichikawa K. Experimentelle Studie über die Pathogenese der Epithelialgeschwülste. Mitteilungen der Medizinischen Fakultät, Universität Tokyo. 15:1915;295-344.
186. Yamaguchi G. Hepatocellular carcinoma and its risk factors - their annual changes and effects on the age at onset. Kurume Medical Journal. 40:1993;33-40.
187. Yamasaki H., Mesnil M., Nakazawa H. Interaction and distinction of genotoxic and non-genotoxic events in carcinogenesis. Toxicology Letters. 64-65:1992;597-604.
188. Yeh F. S., Yu M. C., Mo C. C., Luo S., Tong M. J., Henderson B. E. Hepatitis B virus, aflatoxins and hepatocellular carcinoma in Southern Guangxi, China. Cancer Research. 49:1989;2506-2509.
189. Yuspa S. H. Molecular and cellular basis for tumor promotion in mouse skin. Princess Takamatsu Symposia. 14:1983;315-326.
190. Yuspa S. H. Cutaneous chemical carcinogenesis. Journal of the American Academy for Dermatology. 15:1986;1031-1044.
191. Yuspa S. H. The pathogenesis of squamous cell cancer: Lessons learned from studies of skin carcinogenesis - thirty-third G. H. A. Clowes Memorial Award Lecture. Cancer Research. 54:1994;1178-1189.
192. Yuspa S. H., Hennings H., Saffiotti U. Cutaneous chemical carcinogenesis, past present and future. Journal of Investigative Dermatology. 67:1976;199-220.
193. Yuspa S. H., Kilkenny A., Cheng C., Roop D., Hennings H., Kruszewski F., Lee E., Strickland J., Greenhalgh D. A. Alterations in epidermal biochemistry as a consequence of stage-specific genetic changes in skin carcinogenesis. Environmental Health Perspectives. 93:1991;3-10.
194. Zerban H., Preussmann R., Bannasch P. Quantitative morphometric comparison between the expression of two different marker enzymes in preneoplastic liver lesions induced in rats with low doses of N-nitrosodiethanolamine. Cancer Letters. 43:1988;99-104.